While there is some data to indicate that exercise may improve well-being and diminish symptoms of depression and anxiety, the results have been mixed. Â A recent randomized controlled trial has explored the efficacy of [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on preventing postpartum depression with Ob.Gyn News on January 30, 2019 The last decade [...]
In the earliest studies, postpartum depression was described an episode of depression associated with childbirth, typically emerging within the first three months after delivery. Â As more research has been carried out, we have learned [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
In a recent study from Quebec, researchers compared the risk of postpartum depression in more than 35,000 pregnant women with asthma and almost 200,000 women without asthma. Â They found that rates of postpartum depressive symptoms [...]
In a recent meta-analysis, researchers screened electronic databases and analyzed data from randomized controlled trials (RCTs) of acupuncture for the treatment of postpartum depression (PPD). Primary outcomes included improvement in depressive symptoms, as by scores [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. Â We saw the preliminary [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially [...]
A history of maternal psychiatric illness has been linked to postpartum depression (PPD), but this does not account for all instances of postpartum psychiatric illness. A recent study examined the impact of medical complications during [...]
